These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238 [TBL] [Abstract][Full Text] [Related]
9. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system. Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412 [TBL] [Abstract][Full Text] [Related]
10. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD. Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761 [TBL] [Abstract][Full Text] [Related]
11. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067 [TBL] [Abstract][Full Text] [Related]
13. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Yue Y; Pan X; Hakim CH; Kodippili K; Zhang K; Shin JH; Yang HT; McDonald T; Duan D Hum Mol Genet; 2015 Oct; 24(20):5880-90. PubMed ID: 26264580 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy. Wong TWY; Cohn RD Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172 [TBL] [Abstract][Full Text] [Related]
15. Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model. Kodippili K; Hakim CH; Pan X; Yang HT; Yue Y; Zhang Y; Shin JH; Yang NN; Duan D Hum Gene Ther; 2018 Mar; 29(3):299-311. PubMed ID: 28793798 [TBL] [Abstract][Full Text] [Related]
16. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy. Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865 [TBL] [Abstract][Full Text] [Related]
17. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy. Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179 [TBL] [Abstract][Full Text] [Related]
18. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Asher DR; Thapa K; Dharia SD; Khan N; Potter RA; Rodino-Klapac LR; Mendell JR Expert Opin Biol Ther; 2020 Mar; 20(3):263-274. PubMed ID: 32031420 [No Abstract] [Full Text] [Related]
19. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD). Kawecka K; Theodoulides M; Hasoglu Y; Jarmin S; Kymalainen H; Le-Heron A; Popplewell L; Malerba A; Dickson G; Athanasopoulos T Curr Gene Ther; 2015; 15(4):395-415. PubMed ID: 26159373 [TBL] [Abstract][Full Text] [Related]